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Abstract
Background: Dual specificity phosphatases are a class of tumor-associated proteins involved in the negative
regulation of the MAP kinase pathway. Downregulation of the dual specificity phosphatase 2 (DUSP2) has been
reported in cancer. Epigenetic silencing of tumor suppressor genes by abnormal promoter methylation is a
frequent mechanism in oncogenesis. It has been shown that the epigenetic factor CTCF is involved in the
regulation of tumor suppressor genes.
Methods: We analyzed the promoter hypermethylation of DUSP2 in human cancer, including primary Merkel cell
carcinoma by bisulfite restriction analysis and pyrosequencing. Moreover we analyzed the impact of a DNA
methyltransferase inhibitor (5-Aza-dC) and CTCF on the epigenetic regulation of DUSP2 by qRT-PCR, promoter
assay, chromatin immuno-precipitation and methylation analysis.
Results: Here we report a significant tumor-specific hypermethylation of DUSP2 in primary Merkel cell
carcinoma (p = 0.05). An increase in methylation of DUSP2 was also found in 17 out of 24 (71 %) cancer cell
lines, including skin and lung cancer. Treatment of cancer cells with 5-Aza-dC induced DUSP2 expression by
its promoter demethylation, Additionally we observed that CTCF induces DUSP2 expression in cell lines that
exhibit silencing of DUSP2. This reactivation was accompanied by increased CTCF binding and demethylation
of the DUSP2 promoter.
Conclusions: Our data show that aberrant epigenetic inactivation of DUSP2 occurs in carcinogenesis and that
CTCF is involved in the epigenetic regulation of DUSP2 expression.
Keywords: Cancer, Dual specificity phosphatase 2, Epigenetic, Merkel cell carcinoma, CTCF, DNA methylation
Background
Dual specificity phosphatases (DUSPs) are negative regu-
lators of mitogen-activated protein kinases (MAPK) that
regulate proliferative signaling pathways, which are often
activated in cancer [1–3]. DUSP2 encodes a dual-
specificity phosphatase that inactivates ERK1/2 and p38
MAPK [4, 5]. DUSP2 has also been found to regulate
p53- and E2F1-regulated apoptosis [6, 7]. Previously it
has been reported that DUSP2 expression is markedly re-
duced or completely absent in many human cancers [8, 9].
Epigenetic silencing of tumor suppressor genes (TSG)
is one of the most relevant molecular alteration that oc-
curs during carcinogenesis [10]. Promoter hypermethyla-
tion of TSG occurs in cancer through methylation at the
DNA level at C5 of cytosine (5mC), when found as a di-
nucleotides with guanine. DNA methylation in CpG
islands of TSG leads to epigenetic silencing of the ac-
cording transcript [11, 12]. The ten-eleven-translocation
methylcytosine dioxygenases (TET1-3) catalyze the oxi-
dation of 5mC and generate cytosine derivatives includ-
ing 5-hydroxymethylcytosine (5hmC) [13, 14]. TET
proteins are involved in diverse biological processes, as
the zygotic epigenetic reprogramming, hematopoiesis
and the development of leukemia [15–17]. The frequency
of 5hmC suggests that these modified cytosine bases play
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an important role in epigenetic gene regulation [18].
Aberrant levels of 5hmC have been reported in hu-
man cancer [19, 20]. Recently it has been shown that
TET proteins bind the CCCTC binding factor (CTCF)
[21]. CTCF is associated with altered expression of
tumor suppressor genes, such as E-cadherin (CDH1),
retinoblastoma 1, RASSF1A, CDKN2A/p16 and TP53
[22–25]. It has also been postulated, that CTCF itself
acts as a tumor suppressor [26, 27].
Here we analyzed the epigenetic inactivation and
regulation of the dual specificity phosphate 2 (DUSP2)
in human cancers. Our data show that DUSP2 is aber-
rantly methylated in primary Merkel cell cancer and in
different human cancer cell lines. Moreover, we observed
that 5-Aza-dC and CTCF induce DUSP2 expression by its
promoter demethylation.
Methods
Primary tissues and cell lines
The analyzed primary tissues include 22 Merkel cell car-
cinoma [28, 29], 20 pheochromocytoma [30, 31], six
small cell lung cancer [32], 12 breast carcinoma [25, 33]
and 12 benign nevus cell nevi [34]. RNA samples from
normal tissues (liver, breast, kidney and lung) were ob-
tained from Agilent Technologies (Santa Clara, USA).
All patients signed informed consent at initial clinical
investigation. The study was approved by local ethic
committees (City of Hope Medical Center, Duarte, USA
or Martin-Luther University, Halle, Germany). All cell
lines were cultured in a humidified atmosphere (37 °C)
with 5 % CO2 and 1× Penicillin/Streptomycin in according
medium. Cells were transfected with 4 μg of constructs on
3.5 cm plates, using Polyethylenimine or X-tremeGENE
HP (Roche Applied Science, Germany). TREx293 cells, that
stably express the Tet repressor (LifeTechnologies), were
transfected with the expression vector pcDNA4TO-CTCF
and selected with Zeocin™ (Invitrogen). CTCF was induced
by tetracycline (5 μl/ml of a 1 mg/ml stock) over 48 h.
Methylation analysis
DNA was isolated by phenol-chloroform extraction and
then bisulfite treated prior to combined bisulfite restric-
tion analysis (COBRA) and pyrosequencing [35]. 200 ng
were subsequently used for semi nested PCR with primer
DUSP2BSU2 (GGGATTTGTATTTGAGAAGTTGGGT
TTT) and DUSP2BSL2 (CCTCCAACCCCATAACCACC)
in a first PCR. For the second PCR DUSP2BSU1
(GTTTTTTTTYGGTGTGTTGGTTTT) and the 5′-bio-
tinylated primer DUSP2BSBIO (CCTCCAACCCCA-
TAACCACC) were used. Products were digested with
0.5 μl TaqI (Fermentas) 1 h at 65 °C and resolved on 2 %
TBE agarose gel. Methylation status was quantified utiliz-
ing the primer DUSP2BSSeq1 (TTTTGTTTTTTT
TTTTAATTTTTTTT) and DUSP2BSSeq2 (GTTTTTTT
GTTTTGTTTTTGTATGGTGTT) and PyroMark Q24
(Qiagen). Five CpGs are included in the analyzed region
with primer DUSP2BSSeq1 and seven in the region ana-
lyzed with primer DUSP2BSSeq2. For in vitro methylation
of genomic DNA we used M.SssI methylase (NEB).
Expression analysis
RNA was isolated using the Isol-RNA lysis procedure
(5′Prime). 25 μg of breast, kidney, liver and lung RNA
of normal human samples were obtained from Agilent
Technologies (Santa Clara, CA, USA). RNA was DNase
(Fermentas GmbH, St.Leon-Rot, Germany) digested and
then reversely transcribed [36]. RT-PCR was performed
with primers listed in Additional file 1: Table S1. Quanti-
tative PCR (qRT-PCR) was performed in triplicates with
SYBR® Select Master Mix (Life Technologies) using
Rotor-Gene 3000 (Corbett Research, Qiagen).
Promoter assay
The DUSP2 promoter was amplified with primers
DUSP2BglIIU1: CAGATCTGAGTGGCTTGGGACAG
GTCA and DUSP2PromL1: CAGCAGCAGCGTGCG
TTCCG from genomic DNA. The 454 bp promoter frag-
ment was cloned into the BglII sites of pRLnull (Pro-
mega, Mannheim, Germany) and sequenced. In vitro
methylation of the promoter construct was done with
M.SssI methylase (NEB, Frankfurt, Germany). HEK293
were transfected with 1 μg of pRL-DUSP2 promoter
construct and 0.35 μg of pGL3 control vector (Promega,
Mannheim, Germany). Cells were isolated 24 h after
transfection and studied using Dual-Luciferase Reporter
Assay (Promega, Mannheim, Germany).
Depletion of CTCF by RNAi
Five small interfering RNAs against CTCF: HSS173820
(Stealth siRNA), HSS116456 (Stealth siRNA), HSS11
6455 (Stealth siRNA), siCTCF1: UCACCCUCCUGAG
GAAUCACCUUAA, siCTCF2: GAUGCGCUCUAA
GAAAGAA and a control siRNA: CUACGAUGAAG
CACUAUUATT were obtained from Invitrogen (Carlsbad,
CA, USA) and have been characterized previously [37, 38].
Cells were transfected with a pool of five specific siRNAs
against CTCF or a control siRNA according to the
manufacturer manual using Lipofectamin RNAiMax
from Invitrogen (Carlsbad, CA, USA) on two con-
secutive days and incubated for a total of 96 h. RNA
and protein was isolated.
Chromatin immunoprecipitation (ChIP)
Cells were fixed using 37 % formaldehyde (CalBiochem)
with a final concentration of 1 % for 10 min at room
temperature. Incubation of 1/7 volume of 1 M glycine
for 5 min stopped the fixation process. Cells were
washed with PBS and harvested in PBS + 1 mM PMSF.
Haag et al. BMC Cancer  (2016) 16:49 Page 2 of 12
After centrifugation for 2 min at 2000 rpm at 4 °C the
supernatant was removed and cells were lysed using
1 ml SDS lysis buffer (0,5 % SDS, 10 mM EDTA, 50 mM
Tris HCl pH 8.1) supplemented with protease inhibitors
(Complete Mini, Roche) per 107 cells for 10 min on ice.
After sonification (400-800 bp) the samples were centri-
fuged for 10 min at 4 °C and maximum speed. The
supernatant was diluted 1:10 with dilution buffer (0,01 %
SDS, 1,1 % Triton X-100, 1.2 mM EDTA, 16.7 mM Tris/
HCl pH 8.1, 167 mM NaCl) and 1 ml of the dilution was
used for each ChIP. 10 % of the chromatin used for one
ChIP was preserved as an input sample and stored at
-20 °C. The lysate was pre-cleared by rotation at 4 °C for
2 h using 1 ml of the dilution and 20 μl ProteinG Plus/
ProteinA Agarose (Calbiochem). After centrifugation at
4 °C for 1 min at 2000 rpm the supernatant was incu-
bated with the corresponding antibody: IgG (46540;
Santa Cruz Biotechnologie), Histon H3 (1791; Abcam),
α-CTCF-(N2.2, [39]) rotating overnight at 4 °C. Binding
of the immune-complexes occurs afterwards by incubation
of the chromatin with 20 μl of ProteinG Plus/Protein A
agarose for 2 h at 4 °C. After incubation the beads were
washed for 5 min rotating at 4 °C one time with low salt
buffer (0,05 % SDS, 1 % TritonX100, 2 mM EDTA, 20 mM
Tris/HCl pH 8.1, 150 mM NaCl), one time with high salt
buffer (0,05 % SDS, 1 % TritonX100, 2 mM EDTA, 20 mM
Tris/HCl pH 8.1, 500 mM NaCl), one time with LiCl buffer
(0,25 M LiCl, 1 % NP40, 1 % Deoxycholat, 1 mM EDTA,
10 mM Tris/HCl pH 8.1) and two times with TE buffer
(10 mM Tris, 1 mM EDTA pH 8.0). Chromatin bound to
beads and input material were resuspended in 100 μl TE
buffer, 1 μl of 10 mg/ml RNase was added followed by an
incubation of 30 min at 37 °C. 5 μl of 10 % SDS, 1 μl of
20 mg/ml Proteinase K was added and incubated for fur-
ther 2-4 h at 37 °C. The reverse crosslink was performed
by incubating the samples over night at 65 °C. DNA was
recovered by using QIAquick PCR Purification Kit (Qia-
gen) and PCR amplification with the following primer:
DUSP2CIPU1: TTTGAGGGCCTTTTCCGCTACAAG
AG, DUSP2CIPL1: GCCTCCGCTGTTCTTCACCCAG
TC, DUSP2CIPU2: GGGTGGGCGCAAAAACGGAGGG,
DUSP2CIPL2: CCGGGGCACCATACAAGGGCAGA,
DUSP2CIPU3: GGCCACGTCAC CCTCTCAGTGTCTC,
DUSP2CIPL3: GCCTCAGCCAAGTTGCCCAGACA.
PCR was done with U1/L1 (233 bp), U2/L2 (236 bp)
and U3/L3 (120 bp) for positive site, DUSP2 pro-
moter site and negative site, respectively. Quantitative
PCR was performed in triplicates with SYBR® Select
Master Mix (Life Technologies) using Rotor-Gene
3000 (Corbett Research, Qiagen).
Methylated DNA-immunoprecipitation (MeDIP)
MeDIP was performed according to the protocol of
Mohn et al. [40] with antibodies: IgG (46540; Santa Cruz
Biotechnologie), 5mC (MAb-081-010; Diagenode) and
5hmC (MAb-31HMC-020; Diagenode). The following
primers were used for semi quantitative PCR amplifica-
tion: DUSP2CIPU2: GGGTGGGCGCAAAAACGGAG
GG, DUSP2CIPL2: CCGGGGCACCATACAAGGGCA
GA, bACTRTFW: CCTTCCTTCCTGGGCATGGAGT
C, bACTRTFW: CGGAGTACTTGCGCTCAGGAGGA.
Western blot
Cell lysates were resolved in SDS-PAGE, immuno-
blotted, and probed with primary anti-CTCF (N2.2) and
anti-GAPDH antibody (GAPDH rabbit polyclonal IgG
FL-335, Santa Cruz) [39]. Afterwards an incubation with
HRP-coupled secondary antibodies followed. Immuno-
complexes were detected by enhanced chemilumines-
cence reagent (Western Chemiluminescent Immobilon
HRP-Substrate, Millipore) according to the manufac-
turer’s instructions.
Constructs
CTCF and BORIS were generous gifts from Rainer
Renkawitz (Justus-Liebig-University, Giessen, Germany)
and deletions and mutations were generated with
QuikChange Lightning Site-Directed Mutagenesis Kit
(Promega, Heidelberg, Germany) with the primers
listed in Additional file 2: Table S2.
Statistical evaluation
Statistical analysis was performed using Excel (Microsoft,
Redmond, USA) and GraphPad Quick Calcs (GraphPad
Software, La Jolla, USA). Data are represented as mean ±
standard deviation. Unpaired t-test was used to determine
significant differences between groups. For statistical
analysis of methylation differences between Merkel
cell carcinoma and benign controls a two tailed Fisher
exact test was performed. All reported p-values are
considered significant for p ≤ 0.05.
Results
Aberrant promoter methylation of DUSP2 in human cancer
Previously it has been shown that expression of the
MAPK-specific phosphatase DUSP2 is markedly reduced
or completely absent in many human cancers and that
its level of expression inversely correlates with cancer
malignancy [8]. Here we aimed to dissect the epigenetic
mechanisms involved in the aberrant downregulation of
DUSP2 in carcinogenesis. DUSP2 is located on 2q11.2
(Fig. 1a) and contains a 1011 bp CpG island in its pro-
moter region (chr2: 96810444-96811454, UCSC genome
browser). We analyzed the promoter hypermethylation
of DUSP2 in primary tumors including Merkel cell
carcinoma (MCC), pheochromocytoma, small cell lung
cancer and breast carcinoma by COBRA (Fig. 1 and
Additional file 3: Figure S1). In 12 breast carcinoma, 20
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pheochromocytoma and six small cell lung cancer sam-
ples the DUSP2 promoter was unmethylated (Additional
file 3: Figure S1). Interestingly, 10 out of 22 (45 %) Merkel
cell carcinoma showed a DUSP2 hypermethylation
(Fig. 1b). MCC is a rare but aggressive cutaneous malig-
nancy. In the control tissue (benign nevus cell nevi) only
one out of 12 (8 %) analyzed samples exhibited a DUSP2
hypermethylation (NCN12; Fig. 1b). Thus in MCC a sig-
nificant tumor-specific hypermethylation of DUSP2 was
detected (p = 0.05, two tailed Fisher exact test).
To reveal the epigenetic status of DUSP2 in human
cancers in more detail, we have analyzed the methylation
of its promoter in several human cancer cell lines by
COBRA (Fig. 2a) and by pyrosequencing (Fig. 2b). Human
fibroblasts (HF53) and the HB2 mammary luminal epithe-
lial cells are unmethylated (methylation level <5 %) (Fig. 2a
and b). We detected increased DUSP2 methylation
(level ≥5 %) in lung cancer (A427, H322, A549),
breast cancer (MCF-7, ZR75-1), melanoma (SKMel13,
IGR1, buf1280, SKMel28, MeWo), ovarian cancer
(Skov, Ovar, ES2, OAW42), hepatocarcinoma (Hep2G)
and sarcoma (LMS6/93, U2OS) cell lines (Fig. 2a and b).
Lung cancer cell lines H358 and HTB171, melanoma
C8161, ovarian cancer CAOV3, pancreatic cancer PaCa2,
thyroid cancer FTC133 and HeLa were rather unmethy-
lated (<5 %). Furthermore the embryonic kidney cell line
Fig. 1 Hypermethylation of DUSP2 in primary Merkel cell carcinoma (MCC). a. Structure of the DUSP2 CpG island promoter on chromosome
2q11.2. Vertical lines indicate CpGs and the transcriptional start site is marked. A CTCF motif sequence (GGCAGAGCA; CTCFBSDB2.0) is marked
[47]. Primers used for COBRA and sequencing (Seq1 and Seq2) are depicted by arrows. TaqI restriction sites for COBRA and CpGs analyzed by
pyrosequencing are indicated. The 454 bp DUSP2 fragment for the luciferase promoter assay is indicated. b. Methylation of DUSP2 in
MCC (m =methylated). For COBRA bisulfite-treated DNA from MCC, benign nevus cell nevi (NCN) and in vitro methylated DNA (ivm) was
amplified by semi-nested PCR. First and second PCR products are indicated (439 bp and 303 bp, respectively). Products were digested
with TaqI (+) or mock digested (-) and resolved on 2 % agarose gels with a 100 bp marker (M)
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HEK293 showed an aberrant DUSP2 promoter methy-
lation (29 %). In summary, 17 out of 24 (71 %)
human cancer cell lines exhibited increased DUSP2
promoter methylation.
Decreased expression of DUSP2 is associated with its
promoter hypermethylation
To further analyze the impact of epigenetic regulation of
DUSP2 in carcinogenesis we investigated its expression
in normal tissues and cancer cell lines (Fig. 3). DUSP2
expression was found in normal breast, kidney, liver,
lung tissues and in HEK293 cells (Fig. 3a). In HEK293
cells a genome wide expression array (human ST1.0 S,
Affymetrix) detected a 0.02-fold reduced level of DUSP2
compared to beta-actin [41]. We cloned a 454 bp frag-
ment of the DUSP2 promoter in a luciferase reporter
system (Fig. 1a), in vitro methylated (ivm) the construct
and analyzed its activity (Fig. 3b). Methylation of the
DUSP2 promoter construct significantly reduced its ex-
pression (Fig. 3b). In cancer cells lines (H322, ZR75-1)
and HEK293 cells, that exhibit a methylated promoter,
expression of DUSP2 was reduced compared to HeLa
and H358 cells, which harbor unmethylated promoter
regions (Fig. 3c). H322, ZR75-1 and HEK293 cells were
treated with 5-Aza-dC (Aza), a cytidine analogue that in-
hibits DNA methyltransferases and reactivates epigeneti-
cally inactivated TSG [42, 43]. After four days of Aza
treatment an induced expression of DUSP2 was found in
H322, ZR75-1 and HEK293 cells (Fig. 3c). However, in
HeLa and H358 cells, that harbor unmethylated DUSP2
promoters, DUSP2 expression was rather unaffected by
Aza (Fig. 3c). For H322 cells the fourfold increased
DUSP2 expression after 5 μM Aza treatment was corre-
lated with a significant 1.6-fold demethylation of seven
analyzed CpGs at the DUSP2 promoter (Fig. 3d and e).
Thus, we observed a methylation dependent silencing of
DUSP2 in cancer cell lines, which was reversed by inhi-
biting DNA methylation.
Regulation of DUSP2 by the epigenetic factor CTCF
It has been shown that the insulator binding protein
CTCF is involved in the epigenetic regulation of tumor
suppressor genes [22–25, 44, 45]. Wendt and Barksi et al.
have reported that silencing of CTCF by RNA interference
caused repression of DUSP2 in HeLa cells [38, 46]. Data-
base analysis of CTCF ChipSeq Encode data revealed that
Fig. 2 Promoter hypermethylation of DUSP2 in human cancers. a. Combined bisulfite restriction analysis (COBRA) of DUSP2. Bisulfite-treated DNA
from the indicated cancer cell lines, normal epithelial breast cells (HB2) and in vitro methylated DNA (ivm) was amplified, digested with TaqI (+) or
mock digested (-) and resolved on 2 % agarose gels with a 100 bp marker (M). Methylation levels obtained from pyrosequencing are indicated in
percentage. b. Bisulfite pyrosequence analysis of DUSP2 in human cells. The mean methylation levels of five CpGs were analyzed by pyrosequencing
(Seq1). The analysis included the results of three independent experiments. The dashed line marks 5 % threshold
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CTCF binds at the DUSP2 promoter in HeLa cells (chr2:
96811040-96811190) and a search at the CTCFBSDB2.0
site identified a CTCF motif sequence (GGCAGAGCA
chr2: 96811243-96811251) upstream of the DUSP2 tran-
scription start site (Fig. 1a) [47]. To investigate the role of
CTCF in the epigenetic regulation of DUSP2, we per-
formed siRNA mediated knock down of CTCF in
HEK293, HeLa and HTB171 cells (Fig. 4). In HEK293, a
five-fold reduction of CTCF on RNA and protein levels
was accomplished by transfection of CTCF-specific siRNA
(Fig. 4a and b). This downregulation of CTCF resulted in
a 2.5-fold reduction of DUSP2 level (Fig. 4a). Knock down
of CTCF in HeLa and HTB171 cells induced a 1.7-fold re-
duction of DUSP2 (Fig. 4c).
Next, we tested the effect of CTCF overexpression in
cancer cells (Fig. 4 and Additional file 4: Figure S2). In
HEK293 and H322 cells that harbor a methylated
DUSP2 promoter CTCF transfection resulted in a 1.4-
Fig. 3 DUSP2 expression and methylation after 5-Aza-2′-deoxycytidine (Aza) treatment. a. Expression of DUSP2 in normal breast, kidney, liver, lung
tissues (Agilent Technologies) and HEK293 cells was analyzed by qRT-PCR and normalized to ACTB (HEK293 = 1). b. A DUSP2 promoter fragment
(454 bp) was cloned in the pRLnull vector and in vitro methylated (ivm). DUSP2 promoter constructs (DUSP2-pr.) were transfected in HEK293 cells
and expression of renilla luciferase was measured and normalized to the expression of the co-transfected firefly plasmid pGL3.1 (pRLnull = 1). The
analysis included the results (measurement in triplicates) of three independent experiments and significance is indicated (t-test) c. Expression analysis
of DUSP2 in several cell lines after treatment with Aza (0, 5 and 10 μM) for four days. Expression of DUSP2 and ACTB was revealed by semi-quantitative
RT-PCR and products (136 bp and 226 bp, respectively) were resolved on a 2 % agarose gel with a 100 bp marker ladder (M). d. Expression of DUSP2 in
Aza treated H322 cells analyzed by qRT-PCR and normalized to ACTB. Data of three independent experiments, whereby each PCR was performed in
triplicates and significance is indicated (t-test). e. Methylation analysis of DUSP2 after Aza treatment in H322 cells. Methylation of seven
CpGs at proximal DUSP2 transcription start site (Seq2, see also Fig. 1) was analyzed by bisulfite pyrosequencing. Data were calculated from
three independent experiments and significance is indicated (* = p < 0.01; 0 μM vs. 5 μM Aza)
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and 2-fold increased expression of DUSP2, respectively
(Fig. 4d and e). In HeLa cells that exhibit an unmethy-
lated promoter this CTCF-induced expression of DUSP2
was absent (Additional file 4: Figure S2A). The testis-
specific paralogue of CTCF, termed CTCFL or BORIS
was unable to induce DUSP2 expression in HEK293 cells
(Additional file 4: Figure S2B). Previously, it has been re-
ported that SUMOylation and PARylation of CTCF are
involved in its regulatory function [23, 48, 49]. Therefore
we generated different CTCF constructs that lack either
the N- or C-terminal SUMOylation site (K > R substitu-
tion) at position 74 (CTCF-K > R74) and 691 (CTCF-
K > R691), respectively or harbor a deletion of its PARy-
lation sites from position 216 to 243 (CTCF-ΔPAR). Ex-
pression of the two SUMOylation-site deficient CTCF
constructs in HEK293 and H322 cells resulted in a lack
of DUSP2 induction compared to wildtype CTCF (Fig. 4d
and e). Transfection of the PARylation site deficient
CTCF construct (CTCF-ΔPAR) downregulated DUSP2
expression significantly (2.2- and 5.6-fold, respectively)
compared to the vector control in HEK293 and H322
cells (Fig. 4d and e). Furthermore, we have generated a
stable HEK293 cell line (CTCF TREx293) that allows
tetracycline-inducible CTCF expression (Fig. 4f and g).
Fig. 4 CTCF-dependent expression of DUSP2. a. HEK293 cells were transfected on two consecutive days with a pool of five different siRNAs
against hCTCF (siCTCF) or a control siRNA (si ctrl). After 96 h the RNA was isolated and expression of CTCF and DUSP2 was analyzed by RT-PCR
and normalized to ACTB (si control = 1). CTCF knockdown was performed 2 times and the qRT-PCR was done in triplicates and significance is indicated
(same procedure for C). b. Reduction of CTCF protein after RNA interference was analyzed by western blot. GAPDH expression was utilized as control.
c. Reduction of DUSP2 expression after siCTCF transfection in HeLa and HTB171 cells. d. Different CTCF constructs; wildtype, mutated SUMO site K > R
at position 74 (CTCF-K > R74) and 691 (CTCF-K > R691), deletion of CTCF PARylation site (CTCF-ΔPAR) and vector control (pEGFP) were transfected in
HEK293. After two days DUSP2 expression was analyzed by RT-PCR and normalized to ACTB (normal control = 1). Triplicates were determined and the
data of three independent experiment were averaged and significance was calculated (same procedure for e and f) e. Expression of
DUSP2 after transfection of different CTCF constructs in H322 cells (for details see d) f. DUSP2 expression was analyzed in CTCF-inducible
TREx293 cells, a stable HEK293 cell line (CTCF TREx293) that allows inducible CTCF expression by tetracycline (5 μg/ml). After two days expression of
DUSP2 was analyzed by RT-PCR and normalized to ACTB and compared to the uninduced control (unind. = 1). g. Expression of CTCF in TREx293 cells
was analyzed by western blot
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Induction of CTCF in TREx293 cells resulted in 1.6-fold
higher DUSP2 expression (Fig. 4f ).
Increased CTCF binding at the DUSP2 promoter is
associated with reduction in methylation levels and
induced DUSP2 expression
To analyze the mechanism of CTCF regulated DUSP2
expression in detail, we analyzed the binding of CTCF at
the DUSP2 locus in CTCF TREx293 cells by ChIP
(Fig. 5a). Therefore, we utilized CTCF and histone H3
antibody and quantified the precipitation of the DUSP2
promoter, a bona fide CTCF target site at 1 kb down-
stream (positive site) and negative site 1 kb upstream of
the DUSP2 transcriptional start site by qPCR. After
CTCF induction we observed a significant 2.3-fold in-
creased binding of CTCF at the DUSP2 promoter.
Histone H3 binding and CTCF binding at the nega-
tive site were not altered. At the positive site binding
of CTCF was significantly increased by 1.6 times after
tetracycline-induced CTCF expression (Fig. 5a). His-
tone H3 levels were reduced after CTCF induction at
the positive site (Fig. 5a).
Subsequently, we analyzed changes in DNA methyla-
tion after CTCF induction at the DUSP2 promoter
(Fig. 5). Conventional bisulfite sequencing is not able
to distinguish between 5-methylcytosine (5mC) or 5-
hydroxy-methylcytosine (5hmC) levels. Therefore we
precipitated different DNA regions with antibodies
that bind 5mC or 5hmC in induced or uninduced
CTCF TREx293 cells. Interestingly, after CTCF induc-
tion we observed a decrease in 5hmC-precipitated
DUSP2 promoter sequences compared to a control
locus control (chr5q14.1) (Fig. 5b). This result sug-
gests that CTCF induces dehydroxy-methylation of
the DUSP2 promoter. To analyze the effect of CTCF
on the DUSP2 promoter, we performed luciferase
reporter assays (Fig. 5c). Therefore the DUSP2 pro-
moter construct was in vitro methylated (ivm) and
transfected together with CTCF in HEK293 cells.
CTCF transfection significantly induced luciferase
reporter activity of the unmethylated DUSP2 promoter
(1.7-fold) and ivm DUSP2 promoter (1.4-fold) compared
to the pEGFP control vector (Fig. 5c). Moreover CTCF in-
duction in CTCF TREx293 cells resulted in a 1.7-fold
(unmethylated) or 1.5-fold (ivm) increased DUSP2 pro-
moter activity compared to uninduced cells (Fig. 5c).
Taken together these data suggest that CTCF epigeneti-
cally activates DUSP2 expression.
Discussion
Previously it has been reported that DUSP2 expression
is downregulated in many human cancers [8]. However
the mechanism of its silencing was not analyzed in de-
tails. Deletion of the DUSP2 locus at 2q11.2 is rather
infrequent in cancer. Here we show that the promoter of
DUSP2 is hypermethylated in different human cancer
cell lines including lung, breast and skin cancers and in
HEK293 cells (Figs. 1 and 2). In primary Merkel cell can-
cer (MCC) we observed a significant tumor specific
methylation of DUSP2. MCC is one of the most aggres-
sive cancers of the skin and we have reported frequent
hypermethylation of the Ras Association Family Members
RASSF1A and RASSF10 in this tumor entity [28, 29].
Hypermethylation of DUSP2 and murine Dusp2 and has
been reported in breast cancer cell lines, however methy-
lation in primary human mammary tumors was absent
[50], which was also observed in our study (Additional file
3: Figure S1). By inhibiting DNA methyltransferases with
the cytidine analogue 5-aza-dC we found that the DUSP2
gene is epigenetically reactivated by its demethylation
(Fig. 3). The promoter methylation of DUSP2 in HEK293
consists of 5mC and 5hmC epigenetic marks (Fig. 5). Add-
itionally, we have revealed that CTCF reactivates DUSP2
and this is associated with demethylation of its CpG island
promoter (Figs. 4 and 5b). CTCF is a DNA binding factor
well known for its multiple functions in gene regulation.
Depending on the participating genetic locus it is involved
in transcriptional activation [51–53], transcriptional re-
pression [54, 55] or enhancer blocking [56]. Here we show
increased binding of CTCF to the DUSP2 promoter
(Fig. 5a) and CTCF-dependent induction of the DUSP2
promoter activity (Fig. 5c). Thus it will be interesting to
analyze the exact mechanism of CTCF induced DUSP2
expression and promoter dehydroyx-methylation in fur-
ther details.
DUSP2 encodes a dual-specificity phosphatase that in-
activates ERK1/2 and p38 MAPK [4, 5]. DUSP2 has also
been found to regulate p53- and E2F1-regulated apop-
tosis [6, 7]. Dual-specificity phosphatases are negative
regulators of the MAPK signal transduction, proliferative
pathways that are often activated in cancers [1]. Down-
regulation of DUSP2 was detected in human acute
leukemia coupled with activation of MEK and hyperex-
pression of ERK [9]. Especially in acute myeloid
leukemia, translocation and mutations of TET1 and
TET2 gene are frequently observed [57–59]. Moreover it
has been reported that CTCF binds TET proteins [21].
Thus it will be interesting to analyze if TET proteins are
directly involved in the epigenetic regulation of DUSP2.
Here we observed increased binding of CTCF to its target
site in the DUSP2 promoter after CTCF induction
(Fig. 5a). This binding may alter distinct TET- or DNMT-
associated chromatin complexes at the DUSP2 promoter
region involved in CTCF-regulated DNA methylation as
previously reported [21, 25, 60, 61] and revealed in Fig. 5b.
However CTCF-dependent regulation of DUSP2 may also
involve its function in chromosome configuration, chro-
matin insulation or transcriptional regulation [62, 63].
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Fig. 5 Epigenetic regulation of the DUSP2 promoter by CTCF. a. Binding of CTCF at the DUSP2 promoter analyzed by quantitative ChIP. CTCF
expression was induced in CTCF TREx293 cells by tetracycline (5 μg/ml) for 48 h and uninduced cells were used as control. The chromatin was
prepared, precipitated with a CTCF-, histone H3- or control IgG-antibodies and amplified with gene specific primers for the DUSP2 promoter, a
negative site and a bona fide positive site within the DUSP2 locus. CTCF binding was quantified by qPCR (triplicates from 2 independent experiments)
and significance was calculated. Values of the precipitated sample were normalized to 1 % input (=1). b. Methyl-DNA immunoprecipitation (MeDIP)
analysis of the DUSP2 promoter. MeDIP with 5mC- and 5hmC-antibodies was done with DNA from uninduced or induced CTCF TREx293
cells. The detection of the 5hmC and 5mC level was performed with semi-quantitative PCR of the DUSP2 promoter and a control locus.
PCR products were separated together with a 100 bp marker (M) in 2 % agarose gel. c. Effect of CTCF on the DUSP2 promoter. A DUSP2
promoter fragment (454 bp) was cloned in the pRLnull vector and in vitro methylated (ivm). 2.7 μg DUSP2 promoter constructs (DUSP2-pr.)
were transfected in HEK293 or CTCF TREx293 cells and GFP-CTCF or GFP vector (1 μg each) was co-transfected or CTCF was induced for
24 h, respectively. Expression of renilla luciferase was measured and normalized to the expression control vector or to the co-transfected
firefly plasmid pGL3.1 (300 ng), respectively. Significance is indicated (t-test)
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We also observed that the CTCF paralogue CTCFL/
BORIS was unable to reactivate DUSP2 expression
(Additional file 4: Figure S2). Since the cancer-testis spe-
cific BORIS is aberrantly expressed in cancer, an onco-
genic role for BORIS has been proposed [64, 65]. It was
reported that CTCF, unlike BORIS, cannot bind to
methylated binding sites [66]. Therefore, it is interesting
to note that the CTCF consensus site in the DUSP2 pro-
moter sequence lacks CpG sites (Fig. 1a) and ChIP data
show an enhanced CTCF binding in CTCF induced
TREx293 cells at this site (Fig. 5a). It was also postulated
that CTCF itself acts as a tumor suppressor [26, 27].
CTCF contains a N-terminal PARylation site [49]. Here
we observed that overexpression of CTCF lacking its
PARylation site resulted in repression of DUSP2
expression in H322 and HEK293 cells (Fig. 4d and e).
This result suggests that the PARylation site of CTCF
is important for its activating function. It has been
reported that defective CTCF PARylation and dissoci-
ation from the molecular chaperone nucleolin occurs
in CDKN2A- and CDH1-silenced cells, abrogating its
TSG function [23]. Using CTCF mutants, the require-
ment of PARylation for optimal CTCF function in
transcriptional activation of the p19ARF promoter
and inhibition of cell proliferation has been demon-
strated [49]. In this model CTCF and Poly(ADP-ri-
bose) polymerase 1 form functional complexes [49].
Furthermore, CTCF contains two SUMOylation sites
[48]. Overexpresssion of the CTCF construct with
mutated SUMOylation sites in the CTCF N-terminus
or C-terminus resulted in a lack of DUSP2 reactiva-
tion in the lung cancer H322 and HEK293 cells
(Fig. 4d and e). SUMOylation of CTCF has been as-
sociated with its tumor suppressive function in c-myc
expression [48]. There is also a report that CTCF
SUMOylation modulates a CTCF domain, which acti-
vates transcription and decondenses chromatin [67].
Conclusions
Downregulation of the negative regulator DUSP2 of the
oncogenic MAPK signaling pathway has been reported
in cancer. In the present study we have investigated the
epigenetic regulation of DUSP2 in detail and we show
that DUSP2 is epigenetically silenced by promoter
methylation in human cancer. Especially in primary
Merkel cell carcinoma a tumor-specific hypermethyla-
tion of DUSP2 was revealed. Thus it will be interesting
to further analyzed primary tumor tissues regarding an
aberrant DUSP2 promoter hypermethylation. Moreover
our data indicate that the insulator-binding factor CTCF
is involved in the epigenetic regulation of DUSP2. Fur-
ther research will elucidate the exact mechanism of the
CTCF-mediated induction of DUSP2.
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